GlassScriptPhysician profile
Brandon M Thurow
NPI 1033346358
$9,666.30
in general payments reported to CMS, 2019-2025
52 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $709 · 2021: $1,388 · 2022: $1,246 · 2023: $1,553 · 2024: $1,567 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,847 · Education: $56.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,847.40 |
| Education | $56.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,779.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,018.12 | 2019-2025 | |
| Lilly USA, LLC | $752.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $720.60 | 2021-2025 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $586.29 | 2021-2025 | |
| Novo Nordisk INC | $582.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $525.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $287.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $271.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $239.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.89 | 2019-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $228.13 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.82 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $195.51 | 2022 | |
| Amarin Pharma, INC. | $173.17 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Thurow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.